Veridix AI, a specialized technology-driven Contract Research Organization (CRO) supported by artificial intelligence from Emmes Group, has announced the launch of its advanced protocol digitalization tool. This innovative tool serves as the foundation for speeding up the process of assembling clinical studies by up to 30%. Developed within the unified eClinical platform called Advantage eClinical Cloud, created by Veridix AI, the tool utilizes natural language processing (NLP) techniques combined with artificial intelligence to extract structured data elements from unstructured text in clinical evaluation protocols. These structured data elements include visit schedules, cohorts, and electronic case report forms (eCRF).
Trained and optimized using existing data from clinical evaluations, the tool automates the generation of visit schedules and provides a list of predicted eCRFs with an accuracy of over 82%. Clinical evaluation processes have traditionally been burdened by slow, manually performed procedures that are prone to errors. One such process is the assessment of protocols to determine the necessary elements for study compilation. This new concept, therefore, applies specific applications of artificial intelligence to expedite clinical studies and improve data quality.
“Protocol digitalization has the potential to change how information from protocols is utilized throughout the entire process and ecosystem of clinical studies. By leveraging NLP and AI technologies, we are automating further parts of the clinical evaluation process. This is just one example of how we are incorporating more technologies and AI into the clinical research process,” stated Rama Kondru, CEO of Veridix AI.
Upcoming versions of the Advantage eClinical Cloud platform will offer an integrated workflow for transforming protocols into structured data elements, as well as automated eCRF creation and related AI-based edit checks.
“This unique feature helps us expedite the study assembly process and allows our data managers to focus on value-added work instead of manual, time-consuming processes,” said Sastry Chilukuri, CEO of Emmes Group. “We are already implementing this feature in over 40 new studies across our government and commercial portfolio,” Chilukuri added. “This highlights our commitment to improving clinical studies through the use of next-generation technologies and the capabilities of artificial intelligence.”
About Emmes Group:
Emmes Group is a privately-owned Contract Research Organization (CRO) fully owned by New Mountain Capital (https://www.newmountaincapital.com). The company is shaping the future of clinical research and bringing the promise of new medical discoveries within reach of patients. Founded over 47 years ago as Emmes, the company has become a leading provider of clinical research for the U.S. government, expanding into public-private partnerships and commercial bio-pharmaceutical research. Today, Emmes Group is transforming clinical research by building the first specialized technology and AI-driven CRO, optimized for faster, better, and more efficient program execution. Here, human and artificial intelligence converge. For more information, visit www.theemmesgroup.com.
About Veridix AI:
Veridix AI is the technology and AI division of Emmes Group, dedicated to pioneering AI development and patient-focused technologies. We are passionate about serving patients by bringing the latest technological and analytical advancements to clinical research. Through continuous innovation, we strive to accelerate the pace of clinical studies and facilitate faster access to new treatment approaches for patients. By combining our expertise with the operational and scientific excellence of Emmes CRO, we are modernizing clinical research. Learn more at www.veridixai.com.